Taiwo Olabisi: Exploring the Promise of Factor XIa Inhibitors in Stroke Prevention
Taiwo Olabisi, Registered Nurse at Lasuth, shared a post on LinkedIn:
“Closed my laptop today feeling incredibly fulfilled. I just completed an advanced pharmacotherapy certification: ‘Less Bleeding, More Prevention: A Nurse-Focused Review of the Paradigm-Shifting Promise of Factor XIa Inhibitors in Secondary Stroke Prevention.’
While working in a busy surgical department, you quickly realize that patient care doesn’t stop when the surgery ends.
Post-op recovery is a critical window, and thromboembolic events (like strokes or deep vein clots) are risks we have to watch like a hawk every single shift.
Taking this course gave me a much deeper look into the latest low-bleed anticoagulation protocols, which means I can bring sharper eyes and better clinical judgment straight to the ward floor tomorrow.
Investing in my education is non-negotiable for me, especially as I keep looking toward global standards and expanding my horizons in healthcare.
One milestone at a time!”

Stay updated with Hemostasis Today.
-
Nov 11, 2026, 15:42Tareq Abadl: The Clinical Impact of Kell Alloimmunization
-
Nov 11, 2026, 15:30Alejandro González Veliz: Does PCI Change The Long-Term Outcome In Stable Coronary Artery Disease?
-
Nov 11, 2026, 15:25Preparing for the SoHO Regulation – EBA Board Convenes in Vienna – European Blood Alliance
-
Nov 11, 2026, 15:20Vaidehi Prasanth: IV Iron in Heart Failure – Exploring Hospitalisation Benefits vs. Infection Risk in Open Heart
-
Nov 11, 2026, 15:18Stefan Prendić: Can Algorithms Support Antibody Identification in Immunohematology?
-
Nov 11, 2026, 15:12Perioperative Challenges in Hemophilia Patients on Rebalancing Therapies
-
Nov 11, 2026, 15:03Maria Elisa Mancuso: World-Renowned Faculty and 33 Global Participants Unite at Hemophilia Academy 2026
-
Nov 11, 2026, 15:01Hassan Raza: The JAK2 V617F Revolution
-
Nov 11, 2026, 14:57Edward Lee Carter: Factor Xla Inhibition Enters Clinical Practice – FDA Approval of Asundexian